kynostatin 272 has been researched along with nelfinavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blum, LE; Clemente, JC; Dunn, BM; Goodenow, MM; Hemrajani, R | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Kimura, T; Kiso, Y; Nakahara, K; Nakatani, S; Nguyen, JT; Sato, A | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Hori, Y; Kimura, T; Kiso, Y; Nagai, A; Nakahara, K; Nakatani, S; Nguyen, JT; Ohnishi, N; Sato, A | 1 |
3 other study(ies) available for kynostatin 272 and nelfinavir
| Article | Year |
|---|---|
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine | 2003 |
Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
Topics: Amides; Cell Line; Cysteine; HIV; HIV Protease Inhibitors; Humans; Models, Molecular; Phenylbutyrates; Thiazoles | 2007 |
Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Topics: Amino Acids; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Models, Molecular; Mutation; Phenylbutyrates; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2008 |